Literature DB >> 21780105

Proviral loads of human T-lymphotropic virus Type 1 in asymptomatic carriers with different infection routes.

Shiro Ueno1, Kazumi Umeki, Ichiro Takajo, Yasuhiro Nagatomo, Norio Kusumoto, Kunihiko Umekita, Kazuhiro Morishita, Akihiko Okayama.   

Abstract

High human T-lymphotropic virus Type 1 (HTLV-1) proviral DNA load (PVL) has been reported to be one risk factor for the development of adult T-cell leukemia/lymphoma (ATL). ATL is also believed to develop in HTLV-1 carriers who acquire infection perinatally. ATL cells have been reported to frequently harbor defective provirus. In our study, PVLs for three different regions of HTLV-1 provirus (5'LTR-gag, gag and pX) were measured in 309 asymptomatic carriers with different infection routes. PVLs for the pX region in 21 asymptomatic carriers with maternal infection was significantly higher than in 24 carriers with spousal infection. Among 161 carriers with relatively high pX PVLs (equal to or greater than 1 copy per 100 peripheral blood mononuclear cells), 26 carriers (16%) had low gag PVL/pX PVL (less than 0.5) and four (2%) had low 5'LTR-gag PVL/pX PVL (less than 0.5). Low gag PVL/pX PVL ratio, which reflects deficiency and/or polymorphism of HTLV-1 proviral DNA sequences for the gag region, was also associated with maternal infection. These data suggest that HTLV-1 carriers with maternal infection tend to have high PVLs, which may be related to provirus with deficiency and/or the polymorphism of proviral DNA sequences. In addition, there is a possibility that this ratio may be used as a tool to differentiate the infection routes of asymptomatic HTLV-1 carriers, which supports the need for a large scale study.
Copyright © 2011 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21780105     DOI: 10.1002/ijc.26289

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

1.  Proviral Features of Human T Cell Leukemia Virus Type 1 in Carriers with Indeterminate Western Blot Analysis Results.

Authors:  Madoka Kuramitsu; Tsuyoshi Sekizuka; Tadanori Yamochi; Sanaz Firouzi; Tomoo Sato; Kazumi Umeki; Daisuke Sasaki; Hiroo Hasegawa; Ryuji Kubota; Rieko Sobata; Chieko Matsumoto; Noriaki Kaneko; Haruka Momose; Kumiko Araki; Masumichi Saito; Kisato Nosaka; Atae Utsunomiya; Ki-Ryang Koh; Masao Ogata; Kaoru Uchimaru; Masako Iwanaga; Yasuko Sagara; Yoshihisa Yamano; Akihiko Okayama; Kiyonori Miura; Masahiro Satake; Shigeru Saito; Kazuo Itabashi; Kazunari Yamaguchi; Makoto Kuroda; Toshiki Watanabe; Kazu Okuma; Isao Hamaguchi
Journal:  J Clin Microbiol       Date:  2017-07-12       Impact factor: 5.948

2.  Infection of defective human T-lymphotropic virus type 1.

Authors:  Yuuki Hashikura; Kazumi Umeki; Kunihiko Umekita; Hajime Nomura; Akiteru Yamada; Ikuo Yamamoto; Hiroo Hasegawa; Katsunori Yanagihara; Akihiko Okayama
Journal:  Hum Cell       Date:  2017-01-09       Impact factor: 4.174

3.  Identification of TL-Om1, an adult T-cell leukemia (ATL) cell line, as reference material for quantitative PCR for human T-lymphotropic virus 1.

Authors:  Madoka Kuramitsu; Kazu Okuma; Makoto Yamagishi; Tadanori Yamochi; Sanaz Firouzi; Haruka Momose; Takuo Mizukami; Kazuya Takizawa; Kumiko Araki; Kazuo Sugamura; Kazunari Yamaguchi; Toshiki Watanabe; Isao Hamaguchi
Journal:  J Clin Microbiol       Date:  2014-12-10       Impact factor: 5.948

4.  The diversity of the structure and genomic integration sites of HTLV-1 provirus in MT-2 cell lines.

Authors:  Yuuki Hashikura; Kazumi Umeki; Kunihiko Umekita; Hajime Nomura; Ikuo Yamamoto; Hiroo Hasegawa; Katsunori Yanagihara; Akihiko Okayama
Journal:  Hum Cell       Date:  2016-03-03       Impact factor: 4.174

5.  Oral administration of an HSP90 inhibitor, 17-DMAG, intervenes tumor-cell infiltration into multiple organs and improves survival period for ATL model mice.

Authors:  E Ikebe; A Kawaguchi; K Tezuka; S Taguchi; S Hirose; T Matsumoto; T Mitsui; K Senba; A Nishizono; M Hori; H Hasegawa; Y Yamada; T Ueno; Y Tanaka; H Sawa; W Hall; Y Minami; K T Jeang; M Ogata; K Morishita; H Hasegawa; J Fujisawa; H Iha
Journal:  Blood Cancer J       Date:  2013-08-16       Impact factor: 11.037

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.